Jazz Pharmaceuticals INC.

Reporting payments is a legal requirement; large totals often reflect large product portfolios.

$44Mgeneral payments (2019-2025)
$790Kresearch payments (2019-2025)
43,832clinicians paid

General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.

General payments by year

2019 $4.8M
2020 $2.2M
2021 $4.7M
2022 $6.6M
2023 $8.5M
2024 $8.2M
2025 $9.2M

General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.

Products most associated with its payments

Specialties it works with most

Hematology & Oncology $6.6M
Neurology (Psychiatry & Neurology) $4.3M
Sleep Medicine (Psychiatry & Neurology) $3.6M
Pulmonary Disease $3.5M
Pediatric Hematology-Oncology $3.5M
Medical Oncology $3.5M

Clinicians with the largest reported totals

Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.

ClinicianLocationSpecialtyGeneral payments (2019-2025)
Revati Shreeniwas Stanford, CA Pulmonary Disease $725,600.00
Richard Bogan Columbia, SC Pulmonary Disease $669,353.12
Nancy Lynch San Mateo, CA Hand Surgery $581,976.06
John Khoury Abington, PA Neurology (Psychiatry & Neurology) $553,825.59
Mark Smith San Francisco, CA Internal Medicine $533,401.32
Haramandeep Singh San Ramon, CA Sleep Medicine (Psychiatry & Neurology) $517,541.71
Gerard Meskill Sugar Land, TX Sleep Medicine (Psychiatry & Neurology) $503,464.02
William Winter Charlottesville, VA Sleep Medicine (Psychiatry & Neurology) $473,806.94
Michael Strunc Norfolk, VA Neurology With Special Qualifications In Child Neurology $439,831.98
Vikas Jain Frisco, TX Sleep Medicine (Psychiatry & Neurology) $435,832.93

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.